Belite Bio, Inc (BLTE) Stock Price & Analysis
Belite Bio, Inc (BLTE) closed at USD 152.62 on Thursday, October 15, 2026, down 0.07% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 152.72; the Oct 15, 2026 session ranged USD 152.13–155.47 on volume of 195,857 shares. Market capitalization is $6.15B, with a 52-week range of USD 81.01–200 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BLTE.md
Key facts (BLTE)
- 1 of 80 tracked superinvestors hold BLTE (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.78 on a 1–5 scale) (9 analysts), mean target USD 228.89 (range 185–303).
- Total return with dividends: 1Y +71.3% vs S&P 500 +18.1%; 5Y +1341.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.77, revenue estimate $0K.
Superinvestors (SEC 13F-HR, Q2 2026) (BLTE)
1 of 80 tracked investors hold BLTE. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.55% | $61.0M | New position |
Analysts (BLTE)
Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 228.89 (low 185, high 303).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $245 |
| 2026-09-09 | Mizuho | Target raised | Outperform | $220 → $234 |
| 2026-09-08 | HC Wainwright & Co. | Target raised | Buy | $214 → $245 |
| 2026-09-04 | Canaccord Genuity | Initiated | Buy | $303 |
| 2026-08-14 | Morgan Stanley | Target raised | Overweight | $201 → $206 |
| 2026-08-14 | Cantor Fitzgerald | Target raised | Overweight | $266 → $270 |
| 2026-08-12 | HC Wainwright & Co. | Target raised | Buy | $200 → $214 |
Total return (dividends reinvested) (BLTE)
| 1Y (from 2025-10-16) | 5Y (from 2022-04-25) | |
|---|---|---|
| Total return | +71.3% | +1341.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +71.7% | +81.5% |
| Volatility (annualized) | 53.1% | 68.6% |
| Max drawdown | -29.1% (Feb 2026→Jun 2026) | -74.0% (Jul 2022→Jun 2023) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 152.62 |
|---|---|
| Change | ▼ 0.07% (down) |
| Previous Close | USD 152.72 |
| Open | USD 153.87 |
| Day Range | USD 152.13 – 155.47 |
| 52-Week Range | USD 81.01 – 200 |
| Volume | 195,857 shares |
| Market Cap | $6.15B |
| Exchange | NCM |
Technical Analysis (BLTE)
Nexqual's technical model rates BLTE "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.03 (neutral) |
| vs SMA50 | Below (USD 165.37) |
| MACD | -4.04 (negative) |
Analyst Ratings (BLTE)
Wall Street analysts rate BLTE "Buy" based on 9 analysts, with a mean price target of USD 228.89 (range USD 185–303), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 228.89 |
| High Target | USD 303 |
| Low Target | USD 185 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (BLTE)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.77 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.7 vs est -0.78 ▲ beat |
| 2026-03-31 | USD -0.68 vs est -0.64 ▼ miss |
| 2025-12-31 | USD -0.7 vs est -0.54 ▼ miss |
| 2025-09-30 | USD -0.65 vs est -0.49 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (BLTE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -22.10% |
| Current Ratio | 33.56 |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (BLTE)
Nexqual rates Belite Bio, Inc's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -22%, ROA -15.7% |
Ownership (BLTE)
| Insider Ownership | +43.64% |
|---|---|
| Institutional Ownership | +24.27% |
| Shares Outstanding | 40.27M |
| Float | 19.55M |
| Short % of Float | +5.04% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (BLTE)
Belite Bio, Inc is led by Yu-Hsin Lin (age 47), Chairman of the Board of Directors & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman of the Board of Directors & CEO | Yu-Hsin Lin (age 47) |
|---|---|
| CFO & Director | Hao-Yuan Chuang C.F.A., F.R.M. (age 41) |
| Chief Scientific Officer | Nathan L. Mata (age 59) |
Major Backers & Investors (BLTE)
Notable institutional backers of Belite Bio, Inc include Darwin Global Management, Ltd., Paradigm Biocapital Advisors LP, RTW Investments LP, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Darwin Global Management, Ltd. | 7.64% |
| Paradigm Biocapital Advisors LP | 3.06% |
| RTW Investments LP | 1.78% |
| Millennium Management | 1.23% |
| Maverick Capital Ltd. | 0.98% |
| Eventide Asset Management LLC | 0.97% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.97% |
| Deerfield Management Company, L.P | 0.89% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
| ABVX | Abivax SA | USD 92.38 | ▲ 7.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt